

Share Purchase Plan Closing Date Extended

Perth, Australia; 28 December 2017: Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) advises that to allow shareholders additional time to participate in its Share Purchase Plan (Plan) the Closing Date has been extended until **Friday 5 January 2018**.

Under the Plan, OCC is giving eligible shareholders the opportunity to purchase up to \$15,000 worth of fully paid ordinary shares in OCC (Shares) at an issue price of \$0.34 per Share which is the same price as the recently completed placement, irrespective of the size of their shareholding, without incurring brokerage or transaction costs.

The right to participate under the Plan is optional and is available exclusively to shareholders who are registered as holders of Shares at 5.00pm (AEDT) on the Record Date of 12 December 2017 and whose registered address is in Australia or New Zealand.

A revised timetable is set out below:

Record Date for Share Purchase Plan	5pm, AEDT, 12 December 2017
Share Purchase Plan and Placement Announced	13 December 2017
Offer Letter and Section 708A “Cleansing Notice” lodged with ASX	15 December 2017
Share Purchase Plan booklet sent to shareholders	15 December 2017
Share Purchase Plan Opened	18 December 2017
Closing date for Share Purchase Plan	5 January 2018
Lodge Appendix 3B, Issue of new shares under the Share Purchase Plan	12 January 2018
Quotation on ASX of new shares under the Share Purchase Plan	15 January 2018

These dates are indicative only. OCC may vary the dates and times of the Offer without notice. Accordingly, shareholders are encouraged to submit their Entitlement and Acceptance Forms as early as possible.



For more information, please contact:

General enquiries

Paul Anderson

Orthocell Limited, Managing Director

P: +61 8 9360 2888

E: paulanderson@orthocell.com.au

Investor and Media enquiries

Ben Walsh

WE Buchan

P: + 61 411 520 012

E: bwalsh@buchanwe.com.au

About Orthocell Limited

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of tendon, cartilage and soft tissue injuries. Orthocell's portfolio of products include TGA-licensed cell therapies Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue. The Company's other major product is CelGro®, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.

For more information on Orthocell, please visit www.orthocell.com.au or follow us on Twitter **@OrthocellLtd** and LinkedIn www.linkedin.com/company/orthocell-ltd

